Plasma cell leukemia. Unassembled light and heavy chains in the urine.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to A Zlotnick.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Mouse myeloma cells (MPC-11) secreting gamma-2-b globulin were shown to proliferate into solid tumours after transplantation into the hamster cheek pouch. The implanted tumours continued to grow during the first 2 weeks; thereafter they diminished in size and disappeared completely a month after transplantation. The specific MPC-11 gammaglobulin could be detected in the serum of the hosts within 2 days after the transplantation and the changes in its concentration roughly correlated with the tumour size. The estimated half-life of the MPC-11 gammaglobulin in the circulation of the tumour-bearing hamsters was 4-6 days. Host resistance was demonstrated in tumour-bearing hamsters by their failure to develop tumours on second challenge with MPC-11 cells.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
One hundred and fifty-four patients with a monoclonal gammopathy, diagnosed between 1965-1974 in the Hadassah University Hospital are reviewed with special reference to the relative incidence of associated disorders. Most patients (63 per cent) had immunoproliferative disorders (multiple myeoloma, macroglobulinemia of Waldenstrom, chronic lymphocytic leukemia, and other non-Hodgkin lymphomata). A non-B-cell malignancy, either of blood-forming tissues or of epithelial origin, was found in 6.5 per cent. Miscellaneous nonmalignant diseases (chronic liver disease, diseases of known or suspected autoimmune origin, chronic infections, Gaucher's disease), which have been reported in the past in association with a monoclonal gammopathy, were diagnosed in 15 per cent of the patients in this series. Twelve per cent of the patients were either asymptomatic or had diseases not known to be associated with monoclonal gammopathies. Amyloidosis was diagnosed in 3.3 per cent of the patients.
The coexistence of Philadelphia negative chronic granulocytic leukemia (CGL) of the neutrophilic type and IgA monoclonal gammopathy is reported in a patient. The possible relation between the two proliferative processes is discussed in the light of current knowledge on the pluripotent stem cell and the clonal origin of CGL.
Sixty-nine asymptomatic HBsAg carriers have been studied for the presence of laboratory stigmata of connective tissue disorders. Anti-nuclear antibodies accompanied by a significant binding of anti-DNA were detected on one carrier only. In contrast, rheumatoid activity was detected in 10 out of 63 carriers, and lymphocytotoxins in 8 out of 33. Carriers had a significantly increased level of circulating immune complexes associated with mild hypocomplementemia. Since none of the carriers had any evidence of liver disease, it is probable that the immunologic abberations were induced by the persistent viral infection rather than liver injury. It seems that some asymptomatic carriers have an occult laboratory-wise, connective tissue disorder which, under yet unknown circumstances, gives rise to an overt immune complex disease.